Fulcrum Therapeutics (FULC) Change in Accured Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Change in Accured Expenses for 9 consecutive years, with -$1.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 278.36% year-over-year to -$1.0 million; the TTM figure through Jun 2026 stood at -$1.0 million (up 50.53% YoY), while the FY2025 annual figure was $1.0 million, up 199.32% from the prior year.
• Change in Accured Expenses improved to -$1.0 million in Q2 2026 per FULC's latest filing, from -$3.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.8 million in Q2 2022 and bottomed at -$4.5 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged -$282777.8 across 5 years, with a median of $140500.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 289.74% — and 2024, when it soared 525.16%.
• Fulcrum Therapeutics' Change in Accured Expenses stood at $1.6 million in 2022, then plunged by 41.81% to $909000.0 in 2023, then sank by 170.41% to -$640000.0 in 2024, then soared by 457.97% to $2.3 million in 2025, then plunged by 145.7% to -$1.0 million in 2026.
• Business Quant data shows FULC's Change in Accured Expenses at -$1.0 million in Q2 2026, -$3.8 million in Q1 2026, and $2.3 million in Q4 2025.